The current price of ORGO is $0.8132 — it has decreased by 3.18% since the previous close. Data as of Nov 6, 2026.
ORGO is up 4.26% over the past week, down 38.39% over the past month and down 85.56% over the past year. The price is below its 200-day moving average of $2.30.
Analysts' average 12-month price target for ORGO is $2.50, which implies 207.43% upside from the current price. Individual estimates range from $2.00 to $3.00.
Organogenesis Holdings Inc. has a market capitalization of $104.64M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Organogenesis Holdings Inc. posted a loss of $0.25 per share against an estimate of -$0.175, missing expectations by 42.86%. Upcoming reports are listed in the earnings calendar.
Organogenesis Holdings Inc. reported revenue of $45.5M in its most recent quarter, which has decreased by 69.84% compared with the same quarter a year earlier. Analysts had expected $52.1M.
Companies most comparable to Organogenesis Holdings Inc. include Varex Imaging Corporation, Esperion Therapeutics, Inc., AngioDynamics, Inc., Monopar Therapeutics Inc. and Evolus, Inc.
In the latest trading session ORGO moved between $0.75 and $0.9031, a range of 18.83% of its current price.
Over the past 52 weeks ORGO has traded between $0.73 and $7.08. The current price is 88.51% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.